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Abstract Reported incidence of no residual prostate cancer
(i.e. pathological stage pT0) on radical prostatectomy
ranges from 0.07 to 4.2%. The incidence is higher after
neoadjuvant endocrine treatment. The aim of this study was
to search for residual cancer on radical prostatectomy (RP)
specimens when an initial sampling failed to find the cancer
in patients with positive biopsy. Our database of 1,328
consecutive patients whose biopsies and RP specimen were
both examined at the Polytechnic University-United Hos-
pitals of the Marche Region between March 1995 and June
2006 was reviewed. The radical prostatectomies were
grossly completely sampled and examined with the whole
mount technique. We identified eight patients (i.e. 0.6%;
three untreated and five hormonally treated preoperatively,
i.e. 0.3 and 0.8%, respectively, of the total number of RPs
included in the study) with positive biopsy and with no
residual cancer in the initial routine histological examina-
tion of the RP. The RP of this group of eight was subjected
to additional sectioning and evaluation of the paraffin
blocks of the prostatectomy, also after block-flipping,
immunostaining with an antibody against CAM 5.2, p63,
PSA, and alpha-methylacyl-CoA racemase, and DNA
specimen identity analysis. There were no cases with a
false positive biopsy diagnosis, and cancer was not over-
looked or missed in the initial routine histological exami-
nation of any of the 8 pT0 RPs. A minute focus of cancer
(the diameter was always below 2.0 mm) was found on the
additional sections in five. In particular, cancer was found
after block-flipping in one of them. In an additional case,
cancer was eventually discovered after immunostaining
tissue sections for cytokeratin CAM 5.2, for p63 and PSA.
In the remaining two cases (one untreated and the other
hormonally treated), cancer was not found (0.15% of the
1,328 RPs included in the study); the review of the
description of the macroscopic appearance of the RP and
of its slides revealed that part of the peripheral zone
corresponding to the site of the positive biopsy was
missing, i.e. not removed from the patient at the time of
the operation at least in one of the two. DNA specimen
analysis confirmed the identity of the biopsy and prosta-
tectomy in both. An extensive search for residual cancer
reduces the number of pT0 RPs after a positive biopsy from
0.6 to 0.15%. It is recommended to have the needle biopsy
reviewed, carefully look again at the radical prostatectomy,
do deeper sections and then flip certain paraffin blocks. In
addition, atypical foci should be stained for basal cell
markers and often AMACR, especially in hormone-treated
cases. If a block is missing part of the peripheral zone
(capsular incision), this should be commented on. DNA
analysis for tissue identity should be performed when the
other steps have been taken without finding cancer.
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Introduction
In 1995, Goldstein et al. [9] introduced the term vanishing
cancer phenomenon referring to cases with minute or no
cancer on radical prostatectomy after a positive biopsy.
They reported 13 patients with minimal (11 patients) or no
(two patients) cancer in prostatectomy specimens. In two
cases with no residual cancer on RP, they confirmed the
identity of the biopsy and the prostatectomy tissue by DNA
matching.
The Johns Hopkins Hospital group documented a
fivefold increase in the incidence of no residual cancer on
prostatectomy in patients in whom both biopsies and
prostatectomies were performed at that institution between
1997 and 2005 (0.07% in 1997, 0.13% in 2004 and 0.34%
in 2005) [5, 7, 30]. In their first study, they also
documented two cases, one in which the biopsy review
revealed only high-grade PIN and in which a diagnosis of
cancer had been established in another institution, and a
second case in which the possibility of specimen switching
could not be ruled out due to DNA mismatch between the
biopsy and the prostatectomy. Most recently, they have
reported a series of 46 patients, 11 with no residual cancer
on prostatectomy and 35 with minute cancer, and in 40
cases, they documented specimen identity [5]. In five of the
six remaining cases, the results could not be interpreted due
to technical problems, and in one case, the tissue from the
biopsy with cancer did not match the tissue from the radical
prostatectomy.
Bostwick and Bostwick [4] found that 38 patients with
no cancer on prostatectomy, identified among 6,843 radical
prostatectomies performed at Mayo Clinic during a 30-year
period, showed no disease recurrence or progression after a
mean follow-up of 10 years. In their experience, the
incidence of vanishing cancer declined tenfold, comparing
prostatectomies performed before 1980 (2.1% incidence) to
a more recent time interval from 1993 to 1995 (0.2%
incidence). They have estimated the current incidence of
vanishing cancer at 2 per 1,000 radical prostatectomies [4].
Recently, Trpkov et al. [28] found an incidence of no
residual cancer on prostatectomy of 0.67% after ten-core
positive biopsy. They concluded that in most cases, finding
no residual cancer on prostatectomy after additional section-
ing and evaluation may indicate minimal patient disease.
Very recently Zynger et al. [32] reported that their frequency
of finding no residual cancer in RP specimens has increased
from 0% in 2002 to 4.2% in 2006. In Canada, Srigley [25]
has estimated the incidence of no residual cancer after
positive biopsy in his practice at less than 0.5%.
In Germany, the incidence of pT0 in patients with prostate
cancer without neoadjuvant treatment was analysed by
Herkommer et al. [13]. Based on a database of 3,609
patients, no residual prostate cancer was found in 0.8% after
RP. Most men in this pT0 series had previous TURP or open
prostatectomy, which may have eliminated prostate cancer,
whereas in two patients, cytology was used for primary
diagnosis. Only in 0.3% of men with positive prostate needle
biopsies was no residual tumour detected in the prostatecto-
my specimen [13]. The incidence of pT0 patients in a very
recent French study was reported to be 0.5% [6].
No residual cancer may also result from preoperative
endocrine therapy [11, 12, 15, 16, 19, 24, 26]. The
incidence of pT0 after neoadjuvant endocrine therapy for
prostate cancer is reported to be higher than in untreated
patients [11]. Kollermann et al. [16] analysed a group of
174 men who underwent prolonged androgen deprivation
therapy and observed a pT0 in 36 of 174 men (21%).
Several questions are addressed to explain why cancer is
not present in a small proportions of prostatectomies.
Cancer is missed during the examination of the RP, all
prostatectomy tissue is not sampled, and the cancer is
overdiagnosed in the biopsy. Pathologists face additional
challenges in eliminating the possibility of laboratory error
resulting in specimen (blocks, slides) mislabelling or
switching and excluding an information system error
resulting in specimen mix-up [28].
The aim of this paper was to report the results of a search
for residual cancer on RP after an initial stage pT0
evaluation in eight patients with positive biopsy.
Materials and methods
We reviewed our database of 1,328 consecutive patients
whose biopsies and RP specimen were examined between
March 1995 and June 2006 at the five Pathological Anatomy
Services associated with the Polytechnic University-United
Hospitals of the Marche Region, Ancona, Italy. Most of the
biopsies and all the RPs of this series of 1,328 patients were
reported by the same pathologist (RM). Seven hundred
patients were untreated before the operation, whereas 628
had received neoadjuvant endocrine treatment for approxi-
mately 3 to 6 months.
The biopsies and RPs were routinely processed as
follows. The core biopsies from each site were submitted
in separate containers. In brief, during biopsy processing,
no more than two biopsy cores were embedded in paraffin
blocks, and all blocks were sectioned at 3 μm and were
stained with haematoxylin–eosin (HE). All cores were
sectioned in two separate levels represented on separate
slides, with each slide containing three additional sections
[28].
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harvested for research) were fixed en bloc in 10% buffered
formalin for at least 24 h and were grossly completely
sampled using a standard protocol [17, 18, 28]. In
particular, each specimen was painted over the surface with
India ink. The seminal vesicles were amputated at the
prostate junction and were grossly completely sampled. The
remainder of the specimen was serially cut with a domestic
electric food slicer calibrated and set to deliver slices which
are 3–4 mm in thickness, representing transverse planes
parallel to the initial apical and basal sections. Each prostate
slide was processed into complete whole mount section,
and one HE slide was routinely sectioned per block. The
apical and basal transverse 2- to 3-mm margins were
sectioned perpendicularly to assess the prostatic apical and
basal margins. Prostatectomies were grossly sectioned in
8.5 slices (mean; range, 6–16), and 15.3 slides (mean;
range, 10 to 20) were generated per prostatectomy. Slides
from pelvic lymph nodes were not included in the reported
number of examined slides.
We identified eight patients with positive 6- to 12-core
biopsy and with no residual cancer (pathological stage pT0)
in the initial routine histological examination of the RP and
successively subjected to additional sectioning and evaluation.
Search for residual cancer
Since 1995, a special cancer searching protocol has been
applied to those RPs in which an initial routine-based
examination does not show residual cancer [18]. As
mentioned earlier, this is basically done in those cases
whose biopsies and RP specimen are both examined at the
Ancona institution.
The following successive steps were undertaken by two
pathologists (RM and RMa). The procedure was usually
stopped at the step where cancer is found.
1. The diagnostic needle biopsies were reviewed to
exclude the possibility of a false positive biopsy
diagnosis and to assess the approximate location of
the biopsy with tumour, such as apex, mid-zone and
base, both left and right.
2. The slides of the surgical specimens were reviewed for
residual cancer that was initially overlooked or missed.
3. If the prostate was not totally embedded, the remaining
prostate tissue was processed in toto. If the prostate was
completely sampled, then this step was skipped. This
type of information was usually contained in the
pathology form where the all the steps of the processing
procedure were recorded. The information was further
confirmed by searching the specimen’s container for
residual pieces. As we routinely sample completely all
prostatectomies, this step was skipped.
4. Additional deeper sections (i.e. three to five sections) of
the prostatectomy area (paraffin block) corresponding
to the location of the core with cancer were re-cut.
Further sections were also obtained from all the other
paraffin blocks.
5. Additional deeper sections (i.e. three to five sections) of
the area corresponding to the location of the positive
core as well as of all the remaining blocks were re-cut
after block-flipping.
6. Immunostains for p63 and alpha-methylacyl-CoA race-
mase (AMACR) were performed to evaluate suspicious
foci (When these two were not yet available, we used
34betaE12 immunostaining).
7. Immunostain for cytokeratin CAM 5.2, for p63 and for
PSA (prostate specific antigen) was performed to identify
the so-called “minimal residual cancer” especially in
patients receiving neoadjuvant hormonal therapy [17].
8. Review the description of the macroscopic appearance
of external and cut surfaces of the surgical specimen as
well as inspect the contour of the tissue sections on the
slides for hint or clues that might indicate that part of
the tissue was missing either due to the surgical
procedure or for technical reasons.
9. DNA specimen analysis was performed on formalin-
fixed tissue to confirm the identity of the biopsies and
prostatectomies whenever necessary.
Table 1 Patients’ clinical data
Patient no. Age (years) PSA Prebiopsy (ng/ml) Digital rectal examination TRUS Gland volume (cc)
1 68 9.0 Abnormal Normal 47.9
2 71 5.4 Normal Abnormal 31.4
3 64 6.1 Normal Normal 28.1
4 67 1.25 Abnormal Normal 93.5
5 60 5.9 Normal Normal 36.6
6 66 3.0 Abnormal Normal 47.9
7 58 3.9 Normal Abnormal 29.3
8 66 6.5 Normal Normal 36.6
Mean (range) 65 (58–71) 5.1 (1.25–9.0) 43.9 (28.1–93.5)
PSA Prostate-specific antigen; TRUS transrectal ultrasound
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Tested samples in an individual case included the biopsy
core with cancer and a random block for the corresponding
RP. The tissue was obtained as a direct section from
formalin-fixed and paraffin-embedded blocks. DNA was
extracted from paraffin-embedded tissue using the QIAmp
DNA mini kit (Qiagen) according to manufacturer’s
protocol (Promega, Madison, WI, USA). Fifteen micro-
satellites and amelogenin locus were co-amplified by the
AmpFlSTR identifiler kit (Applied Biosystems, Foster City,
CA), and the amplified fragments were electrophorized on
an ABIPrism3130 genetic analyzer (Applied Biosystems).
Fragment sizing and allele designation were established by
GeneMapperID v3.2 software (Applied Biosystems), and
genetic profiles from both biopsy and prostatectomy
samples were compared.
Results
Residual cancer was not found in eight RPs after an initial
routine examination. They represent 0.6% of the 1,328
consecutive patients. Three (0.2%) of them were from the
group of untreated patients, whereas five (0.4%) were from
those who had received neoadjuvant treatment. The latter
figure represents 0.8% of the treated patients.
Patients’ clinical data are summarised in Table 1.T h e
mean age of the patients was 65 years (range, 58–71 years).
Mean serum PSA pre-biopsy was 5.1 ng/ml (range, 1.25–
9.0 ng/ml). Mean gland volume was 43.9 ml (range, 28.1–
93.5 ml). Digital rectal examination was abnormal in 37% of
patients, and 25% of patients had abnormal transrectal
ultrasound.
Patients’ biopsy findings are shown in Table 2. In all
patients, carcinoma was found in one core. Seven patients
demonstrated biopsy Gleason score of 6 (3+3), whereas in
one, it was 7 (3+4). Cancer occupied approximately 5% of
the core length (Fig. 1) in 6 and 10% of the core in two.
The positive biopsy location was variable, and there was no
side predilection.
Search for residual cancer
There were no cases with a false positive biopsy diagnosis
(step 1). Cancer was not overlooked or missed in any of the
eight prostatectomies (step 2). Each prostate had been
totally embedded (step 3).
Cancer was found on deeper sections (steps 4 and 5) in
five cases. Cancer was in the right and left apex,
respectively, in two of them. Cancer was in the mid-zone
in another two, one in the left and the other in the right. The
fifth was in the left base. In particular, the cancer found in












1 1/12 3+3=6 5 Right apex
2 1/10 3+4=7 10 Right apex
3 1/6 3+3=6 5 Left mid-zone
4 1/6 3+3=6 5 Right mid-zone
5 1/6 3+3=6 5 Right mid-zone
6 1/12 3+3=6 10 Left mid-zone
7 1/10 3+3=6 5 Right mid-zone
8 1/12 3+3=6 5 Left base
Fig. 1 Biopsy finding of a
small groups of atypical acini
(a) devoid of basal cells (b).
Section immunostained for p63
(case no. 5). The diagnosis is
acinar adenocarcinoma, Gleason
score 3+3=6. (The prostatecto-
my findings are those seen in
Fig. 2)
Fig. 2 Paraffin blocks, original sections and additional sections before
and after block-flipping in case no. 1. a Is the right apex. b Is the left
apex. c Includes the whole mount sections of the body of the prostate.
d Is the right and left base. e Includes the seminal vesicles and deferens.
A1 is the paraffin block. A2 is the original H-E-stained section. A3
includes the additional sections before block-flipping. A4 refers to the
additional sections after block-flipping (Block-flipping was done only
for a and b). The dotted area (see also the red arrow) on the A4 slides
is that of the cancer. It corresponds to the lesion of the biopsy seen in
Fig. 1. The same identification procedure applies to b.C o n c e r n i n gc
and d the paraffin blocks, the original sections and the additional
sections (block-flipping was not done) are shown. For e the paraffin
blocks and the original sections are shown. (Other slides contain some
annotations and abbreviations to indicate additional findings, slide
orientation, and section order, etc.)
b
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5; Fig. 2). The location corresponded to site of the positive
biopsy in four cases. Two out of five cases were from the
untreated group and showed a Gleason score of 3+3=6.
Three cases had the morphologic appearance of cancer with
evident regressive changes due to endocrine therapy. The
diameter of the tumour, measured on the slides, was always
below 2.0 mm. In one of the three treated cases, an
additional focus of cancer was seen at a distance from to
that of the positive biopsy.
The definitive diagnosis was established on steps 6 and 7
in an additional case (the patient was hormonally treated
before RP) where cancer was not seen in the additional
sections even after block-flipping. Immunohistochemistry
for p63 and AMACR was applied to a small suspicious
focus of crowded acini. There were a few scattered p63
positive (basal) cells, whereas AMACR was negative. The
focus was considered to be benign (i.e. atrophy). Cancer was
discovered after immunostaining for cytokeratin CAM 5.2,
for p63 and PSA. It was represented by scattered isolated
cells positively immunostained with the antibody against
CAM 5.2 (Fig. 3) and with PSA and negative for p63
(Fig. 3). The diameter of the focus was 1.0 mm. The block
selected for immunohistochemistry corresponded to an
H&E-stained slide with hypercellular stroma. There was no
exact correspondence with the site of the positive biopsy.
In the remaining two cases (one untreated and the other
treated preoperatively), cancer was not found on steps 4
through 7. The review of the description of the macroscopic
appearance and the inspection of the contour of the tissue
sections on the slides revealed that part of the peripheral
zone of the prostate was missing (Fig. 4). This corre-
sponded to the location of the positive biopsy (step 8).
DNA specimen analysis confirmed the identity of the
biopsy and prostatectomy in both cases (step 9; Table 3).
Incidentally, prostate tissue was documented clinically in
one of the two patients (patient no. 7, hormonally treated
before operation; the same patient whose prostate is shown
in Fig. 4). In particular, a biopsy of the residual fragment
showed normal prostate tissue and adenocarcinoma with
features identical to those seen in the preoperative biopsy.
Discussion
Reported incidence of no residual cancer on RPs ranges
from 0.07 to 4.2% (1–11, 20). It is higher after neoadjuvant
hormonal treatment [16].
There are multiple reasons why cancer may not be found
on RP after a positive biopsy. In some cases, the cancer
may be minute and completely removed by the initial
procedure, either needle biopsy or transurethral resection of
prostate. Small cancers may be removed from the RP
during the technical preparation of the specimen, such as
leveling of the paraffin blocks. Small cancer foci can also
Fig. 4 Whole mount section (case no 7). Part of the peripheral zone,
posteriorly, is missing
Fig. 3 Cancer is discovered after immunostaining for cytokeratin
CAM 5.2 (case no. 6). It is represented by scattered isolated cells. The
same cells are negative for the basal cell marker p63 and positive for
PSA. Part of an atrophic duct is also present
Table 3 Results of the search for residual cancer
Patient no. Neoadjuvant
treatment
Cancer found ID test done
1 No In recut No
2 No In recut No
3 Yes In recut No
4 Yes In recut No
5 Yes In recut after
block-flipping
No
6 Yes After cytokeratin
stain
No
7 Yes Not in RP
a Yes, identical
8 No No Yes, identical
aA post-operative biopsy of the residual prostate fragment in the
patient showed normal prostate tissue and adenocarcinoma with
features identical to those seen in the preoperative biopsy.
376 Virchows Arch (2007) 450:371–378be completely obscured if the patient has undergone
antiandrogen therapy or the RP shows extensive inflamma-
tion or granulomatous inflammation. Other reasons include
false-positive diagnosis on the initial biopsy, resulting in
cancer overdiagnosis, or false-negative diagnosis rendered
on the RP. Review of the material by a second pathologist
or a specialist in urological pathology can often resolve the
latter scenario. Lastly, errors may occur either before a
specimen is submitted for pathological assessment or in the
pathology laboratory. These errors include switching of
patients’ requisitions, mislabelling or switching of speci-
men containers, mislabelling or switching slides or blocks
and information system errors (e.g. incorrect case entry in
the information system or mixed accession numbers) [28].
In our study, the incidence of RPs with no residual
cancer after an initial routine examination of the 1,328
specimens was 0.6%. This figure includes both untreated
and hormonally treated patients. The incidence was 0.2 and
0.4%, respectively, of the total number of RPs included in
the study, or 0.4% (3 out 700 untreated patients) and 0.8%
(5 out 628 treated patients) when the two groups were
considered separately. The former is well in the range of
values reported in the literature for untreated patients and
very close to the figure published by Herkommer et al. [11,
13]. The latter value seen in our treated patients is much
lower than that observed by Kollermann et al. [16].
Additional sectioning and evaluation of the cases can
reduce the number of pT0 RPs after a positive biopsy. In
particular, the current study showed that the final incidence
was 0.15% and included only two RPs with missing parts,
probably due to incomplete removal of the prostate. One of
these two patients was hormonally treated preoperatively.
Our findings on the role of immunohistochemistry to
detect residual PCa cells are in agreement with previous
studies. Gleave et al. [8] found that 50% of the cases that
exhibited no residual cancer on routine pathologic assess-
ment had remaining foci of cancer discovered by immu-
nostaining. Without the aid of additional step sections and
immunostaining for cytokeratin, these cases would have
been reported as being stage pT0 [2].
DNA identity on formalin-fixed tissue from the paraffin
blocks is a useful test to establish specimen identity and to
exclude the possibility of laboratory error when no residual
cancer is found on RP after a positive biopsy. In particular,
DNA analysis is a useful test that eliminates the possibility
of specimen mishandling or switching by establishing the
identity of the tissue from the positive biopsy and the RP. It
can be performed in the formalin-fixed tissue from the
paraffin blocks. Different methods are used to investigate
tissue specimen identity. These include immunolabeling of
blood group antigens [22], sex chromosome targeting using
fluorescence in situ hybridization [21] and microsatellite
analysis. According to some authors, microsatellite analysis
is the gold standard for investigating tissue identity [1, 10,
23, 28, 31].
In our study, the clinical and the biopsy data in patients
with no initial residual cancer on radical prostatectomy after
positive biopsy are similar to the findings from a recent
study in patients with single-core positive biopsies and
minimal cancer on biopsy [28, 29]. The majority of patients
with no residual cancer on prostatectomy demonstrated
minute cancer foci in one or two biopsy cores with Gleason
score of 6, which, in many cases, may reflect minimal
disease [28]. Rare small-volume cancers of higher grade may
also be encountered [28]. Follow-up investigations have, in
general, shown that no pT0 patient has clinical or biologic
evidence of prostate cancer recurrence or progression [6, 14,
20, 27].
There are four aspects that we have not explored in our
study. One is that the carcinoma could be lost in facing off
of the paraffin blocks. We are fully aware of this potential
problem. Our technicians are instructed so that they have to
collect tissue sections and not waste material when the
paraffin blocks are levelled off. The second is whether the
time, effort and expense of the sampling described in this
paper are warranted on a routine basis for all pT0 cases. We
have not done any analysis in these respects due to the fact
that the number of cases is very small and that time and
expense do not represent an issue of concern in our
institution. The third is what degree of sampling would be
necessary to serially section through the entire prostate.
Probably thousands of sections would be required, and we
were prepared to cut as many sections as needed to find
cancer. The fourth is whether there is an outcome difference
when the initial pT0 carcinomas are detected after more
thorough sampling vs pT0 cases without additional sam-
pling. This was not addressed in our study because the
basic aim was to avoid that a pT0 report is rendered to the
clinician and to the patient, thus triggering a potential legal
issue with all the problems related to it.
There are few observations in the literature on pT0 cases
and preoperative diagnosis of cancer made in TURP speci-
mens. The real incidence of no residual cancer after cancer
detected by TURP material is not known and is reported to
be seen in 6 to 39% of cases [9], presumably due to tumour
ablation during the initial resection. However, studies of this
phenomenon are limited by variations in the number of
tissue sections submitted for histological evaluation and by
the small number of cases [3].
Conclusions and recommendations
The current study showed that an extensive search for
residual cancer reduces the number of pT0 RPs after a
positive biopsy. To achieve this, it is recommended to have
Virchows Arch (2007) 450:371–378 377the needle biopsy reviewed, carefully look again at the radical
prostatectomy, do deeper sections and then flip certain
paraffin blocks. In addition, atypical foci should be stained
for basal cell markers and often AMACR, especially in
hormone-treated cases. If a block is missing part of the
peripheral zone (capsular incision), this should be commented
on. DNA analysis for tissue identity should be performed
when the other steps have been taken without finding cancer.
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